Article Text

THU0583 Quiescence in Active and Inactive Non-Infectious, Intermediate, Posterior, or Panuveitis in Patients Treated with Adalimumab: Visual I and Visual II Trials
  1. R. Landewe1,
  2. I. van der Horst-Bruinsma2,
  3. S. Tari3,
  4. S. Florentinus3,
  5. A. Song3,
  6. M. Kron4,
  7. S. Pathai5,
  8. J. Rosenbaum6
  1. 1University of Amsterdam
  2. 2VU University Medical Center, Amsterdam, Netherlands
  3. 3AbbVie Inc, North Chicago, United States
  4. 4AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany
  5. 5AbbVie Ltd, Maidenhead, United Kingdom
  6. 6Oregon Health & Science University, Portland, United States


Background There is an unmet need for effective therapies for patients (pts) with non-infectious intermediate, posterior, or panuveitis who are at risk for long-term side effects from chronic corticosteroid use. The therapeutic goal in uveitis is to achieve quiescence and adalimumab (ADA) has been shown to lower uveitic flare or vision loss in pts with active (VISUAL I) and inactive (VISUAL II) uveitis1,2. As 40–50% of uveitis pts have accompanying extra-ocular rheumatic associations such as Behcet's disease, sarcoidosis, understanding ocular quiescence will not only aid ophthalmologists but also rheumatologists in the overall management of the pt3.

Objectives To assess the control of inflammation over time in pts treated with ADA in the VISUAL I and II trials.

Methods Adults with non-infectious intermediate, posterior, or panuveitis were enrolled in 2 global phase 3, double-masked trials: VISUAL I (pts with active uveitis despite ≥2 weeks [wk] of prednisone [PS] 10–60 mg/d) and VISUAL II (pts with inactive disease dependent on 10–35 mg/d of PS to maintain inactivity). Pts were randomized 1:1 to receive placebo (PBO) or ADA (80mg wk0, followed by 40mg every other wk from wk1 up to 80wks). In VISUAL I, all pts received a PS burst followed by taper to 0mg by wk15. In VISUAL II, PS taper to 0mg was mandatory by wk19. Quiescence as a pre-specified endpoint was defined as no new active inflammatory lesions and anterior chamber cell grade and vitreous haze grade ≤0.5+. Steroid free quiescence at each visit was additionally reported from wks16–52 for VISUAL I and from wk20- 52 for VISUAL II. Non-responder imputation was used for missing data. Statistical comparison between PBO and ADA was based on Chi-square test. Adverse events (AEs) were monitored.

Results A greater proportion of pts in the ADA group than the PBO group achieved quiescence at each visit in both VISUAL I and VISUAL II. Statistically significance between ADA and PBO groups were observed at each visit from wks6–52 for VISUAL I, excluding wks6 and 12 and from wks8–52, excluding wks12 and 32 for VISUAL II (Fig. A,B).Similar results were observed for pts in steroid-free quiescence. Statistically significant differences between ADA and PBO groups occurred at each visit from wks20–52 for VISUAL I and from wks20–52, except wk32 for VISUAL II (Fig. C,D).Safety data from the VISUAL I and II trials have previously been reported1,2. Rates of AEs were similar between ADA and PBO groups.

Conclusions Pts with non-infectious, intermediate, posterior, or panuveitis achieved significantly higher rates of quiescence and steroid-free quiescence with ADA treatment than PBO in the VISUAL I and II trials. The safety profile of ADA was consistent with the known safety profile across the approved ADA indications.

  1. Nguyen Rheumatol.2015;67(suppl10)

  2. Jaffe Rheum Dis.2015;74(suppl 2):849

  3. Hooper Curr Rheum Rev.2011,7,24–38

Acknowledgement AbbVie funded the VISUAL studies and participated in the interpretation of data, review, and approval of publication. Medical writing support was provided by Gaurav Patki, PhD, of AbbVie.

Disclosure of Interest R. Landewe Grant/research support from: Abbott, Amgen, Centocor, Novartis, Pfizer, Roche, Schering-Plough, UCB and Wyeth, Consultant for: advisory boards for Abbott/AbbVie, Ablynx, Amgen, Astra-Zeneca, BMS, Janssen (formerly Centocor), GSK, Merck, Novo-Nordisk, Novartis, Pfizer, Roche, Schering-Plough, TiGenics, UCB, and Wyeth; is Director of Rheumatology Consultancy BV, I. van der Horst-Bruinsma Grant/research support from: unrestricted research grants from Pfizer, MSD and AbbVie, Consultant for: for AbbVie, MSD, UCB, S. Tari Employee of: full-time employees of AbbVie and may hold stock and/or options., S. Florentinus Employee of: full-time employees of AbbVie and may hold stock and/or options., A. Song Employee of: full-time employees of AbbVie and may hold stock and/or options., M. Kron Employee of: full-time employees of AbbVie and may hold stock and/or options., S. Pathai Employee of: full-time employees of AbbVie and may hold stock and/or options., J. Rosenbaum Grant/research support from: Alcon Research Institute., Consultant for: AbbVie, UCB, XOMA, Santen, Novartis, Medimmune, Cavtherx, Portage, Topivert, Regeneron, Allergan, and Sanofi

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.